Alluvi, formerly BI 4744, offers a notable advance in weight loss treatment. This dual agonist targeting both GLP-1 and GIP sites demonstrates remarkable efficacy in patient trials, possibly surpassing current GLP-1 https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/